Why the study?
Does optimal warfarin anticoagulation (TTR ≥75%) improve clinical outcomes in patients with atrial fibrillation?
Does optimal warfarin anticoagulation (TTR ≥75%) improve clinical outcomes in patients with atrial fibrillation?
In patients with atrial fibrillation, lower time in therapeutic range on warfarin is associated with worse clinical outcomes and is more common in females, minorities, and those with prior MI or not on beta-blockers.
Answers are grounded in this paper and cite their sources.
Lower TTR on warfarin was associated with higher mortality, stroke/TIA, and bleeding in AF; hypothesis-generating for TTR optimization trials in at-risk subgroups.
Introduction The efficacy of warfarin anticoagulation in atrial fibrillation patients at risk for stroke is related to time in therapeutic range (TTR) with an INR 2.0–3.0. Factors predisposing to low TTR have not been investigated comprehensively. Methods This post hoc analysis of the AFFIRM trial included patients with at least five INR values. “Optimal” anticoagulation was defined as TTR ≥75%; above this level, adjusted-dose warfarin offers the same prognostic benefits as new oral anticoagulants. Binary regression analysis identified independent variables associated with TTR. The impact of TTR on outcomes was assessed further through cox regression analysis. Results Of 3066 AFFIRM patients, the mean TTR was 0.62 SD 0.2. 975 patients (32%) were “optimally” anticoagulated. These subjects were more frequently male, treated with rate control alone and were less likely to have heart failure, diabetes, myocardial infarction, and hepatic or renal failure (all p<0.05). Cox regression analysis demonstrated TTR was a major determinant of all cause mortality (p<0.001), ischaemic stroke or TIA (p=0.003) and major bleeding (p=0.01). Binary regression analysis revealed female gender (p=0.005), minority status (p<0.001), history of myocardial infarction (p=0.02) and non-treatment with β blockers (p<0.001) were associated independently with sub-optimal anticoagulation. Conclusion TTR is related strongly to clinical outcomes. TTR is associated with clinical and demographic characteristics. Knowledge of factors associated with low TTR may help better optimise antithrombotic management.
No takes yet. Share an insight, caveat, or question.
Apostolakis et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: